

Resource Summary Report

Generated by [dkNET](#) on Aug 19, 2026

Keratin, type I; cytokeratin 19 antibody - Kemler, R.; MPI fuer Immunobiologie

RRID:AB_2133570

Type: Antibody

Proper Citation

DSHB Cat# TROMA-III, RRID:AB_2133570

Antibody Information

URL: http://antibodyregistry.org/AB_2133570

Proper Citation: DSHB Cat# TROMA-III, RRID:AB_2133570

Target Antigen: Keratin, type I; cytokeratin 19

Host Organism: rat

Clonality: monoclonal

Comments: Application(s):

FFPE, Immunofluorescence, Immunohistochemistry, Immunoprecipitation, Western Blot;
Date Deposited: 12/22/2004

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: Keratin, type I; cytokeratin 19 antibody - Kemler, R.; MPI fuer Immunobiologie

Description: This monoclonal targets Keratin, type I; cytokeratin 19

Target Organism: mouse, human

Defining Citation: [PMID:6171607](#), [PMID:23006330](#), [PMID:23376645](#), [PMID:21712022](#), [PMID:24700364](#), [PMID:20546735](#), [PMID:6933460](#), [PMID:19747186](#), [PMID:20621380](#), [PMID:21220329](#)

Antibody ID: AB_2133570

Vendor: DSHB

Catalog Number: TROMA-III

Record Creation Time: 20250819T224155+0000

Record Last Update: 20250820T030128+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Keratin, type I; cytokeratin 19 antibody - Kemler, R.; MPI fuer Immunobiologie.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 95 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lan L, et al. (2026) A Jagged1-regulated hybrid-EMT state identifies pancreatic cancer stem cells. Cell reports, 45(2), 116909.

Zhuo M, et al. (2026) A conserved re-epithelialization program underlies malignancy in pancreatic ductal adenocarcinoma. Cancer cell, 44(6), 1270.

Ferreira S, et al. (2026) Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment. Cancer research, 86(13), 3109.

Hanley SE, et al. (2026) Cyclin C promotes pancreatic development and suppresses cancer initiation by maintenance of the autophagy-lysosome pathway. iScience, 29(3), 114949.

Xu Z, et al. (2026) Unbiased niche labeling maps immune-excluded niche in bone metastasis. Cell, 189(11), 3287.

Osorio-Vasquez V, et al. (2026) Patient-derived organoids reveal ductal dysfunction and CFTR-modulator responses in chronic pancreatitis. Cell stem cell.

Michalopoulos MG, et al. (2026) Defects in nephrogenesis result in an expansion of the Foxd1+ stromal progenitor population. Development (Cambridge, England), 153(1).

Wrynn T, et al. (2026) Unveiling critical signaling pathways in the murine salivary gland and the role of midkine. *iScience*, 29(3), 114852.

Roger E, et al. (2026) ATM Deficiency Induces TGF β -Mediated Stromal Programming in Pancreatic Cancer. *Cancer research*, 86(14), 3412.

Ballester M, et al. (2026) Regulatory elements in the Sox9 locus license the initiation of pancreatic ductal adenocarcinoma. *Cell reports*, 45(4), 117176.

Wu Z, et al. (2026) EVC protein regulates Sonic hedgehog signaling during human intervertebral disc development and degeneration. *iScience*, 29(1), 114290.

Ruiz CF, et al. (2026) Diet-induced phospholipid remodeling dictates ferroptosis sensitivity and tumorigenesis in the pancreas. *Cancer discovery*.

Zhou YD, et al. (2026) Tissue-specific tolerance mechanisms and lymph node co-drainage shape T cell immunity in the upper digestive system and pancreatic cancer progression. *Cell reports*, 45(5), 117324.

Zhang Y, et al. (2025) Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer. *Cancer cell*, 43(9), 1677.

Bernardo E, et al. (2025) HNF1A and A1CF coordinate a beta cell transcription-splicing axis that is disrupted in type 2 diabetes. *Cell metabolism*, 37(9), 1870.

Bakiri L, et al. (2025) A new effLuc/Kate dual reporter allele for tumor imaging in mice. *Disease models & mechanisms*, 18(1).

Li X, et al. (2025) Plakophilin 3 drives acinar cell transformation and promotes cancer initiation and progression in pancreas. *Cell reports*, 44(11), 116487.

Kimura N, et al. (2025) Regulatory T cell stability determines the efficiency of bile duct regeneration during cholangitis. *Cell reports*, 44(11), 116557.

Ren L, et al. (2025) Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. *Cancer cell*.

Li H, et al. (2025) Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. *Cell reports. Medicine*, 6(2), 101927.